Baxter International Inc. Share Price Berne S.E.

Equities

BAX

US0718131099

Medical Equipment, Supplies & Distribution

Delayed Berne S.E. 17:00:00 06/04/2023 BST 5-day change 1st Jan Change
38.11 CHF +3.50% Intraday chart for Baxter International Inc. -.--% -.--%

Financials

Sales 2024 * 15.11B 13.81B 1,190B Sales 2025 * 15.66B 14.31B 1,233B Capitalization 17.5B 16B 1,378B
Net income 2024 * 703M 643M 55.36B Net income 2025 * 950M 868M 74.81B EV / Sales 2024 * 1.8 x
Net Debt 2024 * 9.7B 8.87B 764B Net Debt 2025 * 8.8B 8.04B 693B EV / Sales 2025 * 1.68 x
P/E ratio 2024 *
18.5 x
P/E ratio 2025 *
15.2 x
Employees -
Yield 2024 *
3.51%
Yield 2025 *
3.64%
Free-Float 74.27%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 61 30/09/15
Director of Finance/CFO 54 17/10/23
Chief Tech/Sci/R&D Officer - 31/12/16
Members of the board TitleAgeSince
Director/Board Member 73 05/02/17
Director/Board Member 64 09/05/22
Director/Board Member 64 17/02/19
More insiders
Baxter International Inc. specializes in the development, manufacturing and marketing of medical devices and medications intended for healthcare professionals. Net sales break down by family of products as follows: - medicines and medical devices (33.8%): products intended for treating hemophilia (substitution clotting factors) and immune deficiencies (multi-purpose immunoglobins), and used in intensive care (human albumin) and biosurgery (fibrin adhesive, surgical gel, bone substitutes, hemostatic compresses, etc.); - kidney dialysis drugs and equipment (30.1%); - systems for delivering medications and intravenous therapy (15.2%): used in the fields of anesthesia, oncology (chemotherapy and radiation), parenteral nutrition, etc.; - other (20.1%). Export accounts for 52.7% of net sales.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
34.35 USD
Average target price
46.07 USD
Spread / Average Target
+34.11%
Consensus